1 alpha(OH)D3 treatment and procollagen III (PC III) studies in idiopathic myelofibrosis.
Eight patients with idiopathic myelofibrosis (IMF) were treated with escalating doses (0.5 microgram/day to 4.0 micrograms/day) of 1 alpha(OH)D3 for periods up to 6 months. The treatment did not improve the disease parameters in any of the patients under study. No patient demonstrated a decrease in bone marrow fibrosis as determined by serial procollagen (PC III) serum level analysis. Although 1 alpha(OH)D3 was well tolerated at the administered doses, the therapeutic value of this treatment for IMF requires further evaluation.
Tsatalas
C
C
Curtoglou
G
G
Fotopoulos
D
D
Halkia
P
P
Vyzantiadis
A T
AT
Sinakos
Z
Z
D000368:Aged; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy*; D011347:Procollagen / Q000097:blood*
D006887:Hydroxycholecalciferols; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; C008088:alfacalcidol